Skip to main content

Pan Tumor Rollover Study

Recruiting · Phase 2 · NCT03899155

Conditions: Cancer

At a glance

Research payments reported, 2025
$518,201
U.S. investigators named
28
Sites paid
32
Planned or actual enrollment
1,500

About the trial

Sponsor
Bristol-Myers Squibb (with Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals)
Tested
Nivolumab (drug), Ipilimumab (drug), Cabozantinib (drug), Trametinib (drug), Relatlimab (drug), Nivolumab + Relatlimab (drug), Capecitabine (drug), Bevacizumab (drug), Temozolomide (drug), Rucaparib (drug), Daratumumab (drug), Regorafinib (drug), Leucovorin (drug), Fluorouracil (drug), Oxaliplatin (drug), Enzalutamide (drug), Sunitinib (drug), Pemetrexed (drug), Pembrolizumab (drug)
Dates
Started 2019-08-09; completion 2029-08-25
Results posted
Not yet

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

From ClinicalTrials.gov, last updated 2026-11-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $518,201 in research payments for this study in 2025 (33 payments).

Products named: Opdivo

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.